All News

The ASTER 70s trial found that adjuvant chemotherapy provided no significant survival benefit, but caused substantial toxicity in older women with high-risk HR-positive, HER2-negative breast cancer.

A new biosimilar, LY05008, shows comparable efficacy and safety to dulaglutide in managing type 2 diabetes mellitus (T2DM) in Chinese adults.

Discover groundbreaking FDA approvals for shingles, diabetes, and OTC treatment for gut health, enhancing patient care and access to essential medications.

High-density lipoprotein cholesterol, known for protective cardiovascular effects, could play a role in reducing the risk of stress urinary incontinence.

The oral glucagon-like peptide agonist-1 met its primary end point and all secondary end points in a randomized, double-blind, placebo-controlled clinical trial for weight management.

Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.

The FDA approves donidalorsen, the first RNA-targeted therapy for hereditary angioedema, offering significant attack reduction and convenient administration.

New research uncovers complex inflammatory pathways driving asthma flare-ups in children, highlighting the need for personalized treatment strategies.

New research confirms that switching from tocilizumab to its biosimilar, Avtozma, maintains efficacy and safety in patients with rheumatoid arthritis (RA).

The implementation of nonpharmaceutical measures during the COVID-19 pandemic reduced transmission of Streptococcus pneumoniae, a key bacterium that causes pneumococcal disease.

The AAP unveiled its 2025 immunization schedule, challenging CDC guidelines and emphasizing evidence-based vaccine recommendations for children's health.

Palbociclib revolutionizes HR+/HER2- breast cancer treatment, enhancing outcomes with endocrine therapies and promising new combinations for better patient care.

Probiotic supplementation in VLBW preterm infants reduces antibiotic resistance and promotes beneficial gut bacteria, enhancing neonatal health outcomes.

Simplifying complex information through illustrations and storytelling helps patients feel that managing their condition is achievable.

An expert shares how 340B puts independent pharmacies at a competitive disadvantage.

New research uncovers a pathway linking diabetes and heightened blood clot risks, paving the way for innovative treatments to prevent cardiovascular complications.

Research reveals that clinical stage significantly influences survival rates in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Samantha Picking, PharmD, senior director of immunizations at Walgreens, discusses staffing strategies, digital tools, and operational improvements designed to streamline flu vaccination services during the upcoming respiratory season.

Case highlights the importance of careful cocumentation.

Signos CGM empowers users to manage weight effectively through personalized insights and real-time glucose tracking.

The development of multisystem inflammatory syndrome in children infected with SARS-CoV-2 was associated with more marked shifts in metabolic parameters, leading to increased cardiovascular disease risk.

Both preclinical and translational evidence support MET inhibition as a therapeutic approach in patients with small cell lung cancer (SCLC).

Enfortumab vedotin is one of many effective antibody-drug conjugates on the market that can be utilized to improve the treatment of urothelial carcinoma.

Study reveals rituximab outperforms cladribine in managing RRMS, showing superior disease control and improved disability outcomes.

Long-term obesity triggers aging biomarkers in young adults, linking excess weight to accelerated biological aging and chronic health risks.

New research reveals that immunoglobulin replacement therapy fails to lower infection-related hospitalizations in those with chronic lymphocytic leukemia (CLL), raising treatment concerns.

The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.

The law has support from patients, health care providers, pharmacists, and the largest health insurance provider in the state.

Individuals with cognitive and physical disabilities faced difficulties in health care utilization and had reduced rates of preventive cardiovascular screenings during the pandemic.

Precision oncology has shifted, yet pharmacists’ roles remain underutilized.